Nelum Pharma

Executive Summary

Nelum Pharma is a clinical-stage biopharmaceutical company founded in 2020 and headquartered in Cambridge, MA, focused on developing patented small molecule therapies for fibrosis and cancer. Its lead asset, NLM-001, is a hedgehog pathway inhibitor currently in Phase 1 development for pulmonary fibrosis, addressing a significant unmet medical need. The company leverages its expertise in hedgehog signaling to target fibrotic diseases and certain cancers, with preclinical data suggesting potential anti-fibrotic and anti-tumor activity. As a private, early-stage company, Nelum's progress depends on successful Phase 1 results, financing, and strategic partnerships. The company's proximity to the Boston biotech hub provides access to talent and capital. With the hedgehog pathway validated in other indications, NLM-001 could differentiate based on safety and efficacy. However, near-term valuation is speculative pending clinical data.

Upcoming Catalysts (preview)

• Q4 2026Phase 1 interim safety and tolerability data for NLM-001 in pulmonary fibrosis60% success
• Q3 2026Completion of Phase 1 enrollment for NLM-00180% success
• H1 2027Initiation of a Phase 2 study for NLM-001 in IPF or other fibrotic indication30% success